177 related articles for article (PubMed ID: 31230251)
1. Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
Grant CV; Carver CM; Hastings SD; Ramachandran K; Muniswamy M; Risinger AL; Beutler JA; Mooberry SL
Breast Cancer Res Treat; 2019 Sep; 177(2):345-355. PubMed ID: 31230251
[TBL] [Abstract][Full Text] [Related]
2. Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.
Carson C; Raman P; Tullai J; Xu L; Henault M; Thomas E; Yeola S; Lao J; McPate M; Verkuyl JM; Marsh G; Sarber J; Amaral A; Bailey S; Lubicka D; Pham H; Miranda N; Ding J; Tang HM; Ju H; Tranter P; Ji N; Krastel P; Jain RK; Schumacher AM; Loureiro JJ; George E; Berellini G; Ross NT; Bushell SM; Erdemli G; Solomon JM
PLoS One; 2015; 10(6):e0127498. PubMed ID: 26098886
[TBL] [Abstract][Full Text] [Related]
3. (-)-Englerin A-evoked Cytotoxicity Is Mediated by Na+ Influx and Counteracted by Na+/K+-ATPase.
Ludlow MJ; Gaunt HJ; Rubaiy HN; Musialowski KE; Blythe NM; Vasudev NS; Muraki K; Beech DJ
J Biol Chem; 2017 Jan; 292(2):723-731. PubMed ID: 27875305
[TBL] [Abstract][Full Text] [Related]
4. Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.
Rubaiy HN; Seitz T; Hahn S; Choidas A; Habenberger P; Klebl B; Dinkel K; Nussbaumer P; Waldmann H; Christmann M; Beech DJ
Br J Pharmacol; 2018 Mar; 175(5):830-839. PubMed ID: 29247460
[TBL] [Abstract][Full Text] [Related]
5. Na
Muraki K; Ohnishi K; Takezawa A; Suzuki H; Hatano N; Muraki Y; Hamzah N; Foster R; Waldmann H; Nussbaumer P; Christmann M; Bon RS; Beech DJ
Sci Rep; 2017 Dec; 7(1):16988. PubMed ID: 29209034
[TBL] [Abstract][Full Text] [Related]
6. Triple-Negative Breast Cancer Cells Exhibit Differential Sensitivity to Cardenolides from
Pederson PJ; Cai S; Carver C; Powell DR; Risinger AL; Grkovic T; O'Keefe BR; Mooberry SL; Cichewicz RH
J Nat Prod; 2020 Jul; 83(7):2269-2280. PubMed ID: 32649211
[TBL] [Abstract][Full Text] [Related]
7. (-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels.
Akbulut Y; Gaunt HJ; Muraki K; Ludlow MJ; Amer MS; Bruns A; Vasudev NS; Radtke L; Willot M; Hahn S; Seitz T; Ziegler S; Christmann M; Beech DJ; Waldmann H
Angew Chem Int Ed Engl; 2015 Mar; 54(12):3787-91. PubMed ID: 25707820
[TBL] [Abstract][Full Text] [Related]
8. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
10. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
11. TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
Zhang LY; Zhang YQ; Zeng YZ; Zhu JL; Chen H; Wei XL; Liu LJ
Breast Cancer Res Treat; 2020 Jul; 182(1):21-33. PubMed ID: 32415497
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
[TBL] [Abstract][Full Text] [Related]
13. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
[TBL] [Abstract][Full Text] [Related]
14. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
15. MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis.
Dutta P; Sarkissyan M; Paico K; Wu Y; Vadgama JV
Breast Cancer Res Treat; 2018 Aug; 170(3):477-486. PubMed ID: 29594759
[TBL] [Abstract][Full Text] [Related]
16. Aggressive triple negative breast cancers have unique molecular signature on the basis of mitochondrial genetic and functional defects.
Guha M; Srinivasan S; Raman P; Jiang Y; Kaufman BA; Taylor D; Dong D; Chakrabarti R; Picard M; Carstens RP; Kijima Y; Feldman M; Avadhani NG
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1060-1071. PubMed ID: 29309924
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
